Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one
2. Semaxinib
3. Su 5416
4. Su-5416
5. Su5416
6. Sugen 5416
1. Semaxinib
2. Su5416
3. 204005-46-9
4. Su 5416
5. 194413-58-6
6. Su-5416
7. Semoxind
8. Semaxanib (su5416)
9. Tsu 16
10. Z-semaxanib
11. Nsc-696819
12. Vegfr2 Kinase Inhibitor Iii
13. (z)-3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)indolin-2-one
14. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-1h-indol-2-one
15. (z)-su 5416
16. 71ia9s35aj
17. Chembl276711
18. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-1,3-dihydro-2h-indol-2-one
19. 3-(1-(3,5-dimethyl-1h-pyrrol-2-yl)meth-(z)-ylidene)-2-oxo-2,3-dihydroindole
20. 3-((z)-(3,5-dimethylpyrrol-2-yl)methylene)-2-indolinone
21. Su005416
22. Semaxnib
23. Sugen 5416
24. 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-1,3-dihydro-2h-indol-2-one
25. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-2,3-dihydro-1h-indol-2-one
26. Semaxanib [inn]
27. Semaxanib(su5416)
28. Smr000568416
29. Vegf Receptor 2 Kinase Inhibitor Iii
30. Tsu-16
31. Sr-01000076044
32. Semaxanib (usan/inn)
33. Semaxanib [usan:inn]
34. Methylene]-2h-indol-2-one
35. Unii-71ia9s35aj
36. (3z)-3-((3,5-dimethyl-1h-pyrrol-2-yl)methylidene)-1,3-dihydro-2h-indol-2-one
37. (z)-semaxanib
38. (z)-semaxinib
39. Ncgc00094381-03
40. 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one
41. Nsc 696819
42. 2x2m
43. Semaxanib; Su5416
44. Semaxanib [usan]
45. Semaxanib [mart.]
46. H-indol-2-one, 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)-1,3-dihydro-
47. S 8442
48. Schembl8190
49. Semaxanib [who-dd]
50. Lopac0_001110
51. Schembl19571
52. 1,3-dihydro-3-[(3,5-dimethyl-1h-pyrrol-2-yl)
53. Mls001074896
54. Mls001332519
55. Mls001332520
56. Bdbm4810
57. Gtpl5056
58. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one
59. Chebi:91083
60. Cid_5329098
61. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one
62. Bdbm497339
63. Dtxsid801025708
64. Hms2234l12
65. Hms3229o13
66. Hms3263m22
67. Hms3268j13
68. Hms3413h10
69. Hms3648o12
70. Hms3677h10
71. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]indolin-2-one
72. Amy10847
73. Bcp06068
74. Ex-a2158
75. Tox21 111271
76. Tox21_501110
77. Hsci1_000303
78. Mfcd09763655
79. Nsc696819
80. S2845
81. Su5146
82. Zinc12410091
83. Akos015994557
84. Ccg-205186
85. Cs-1225
86. Db06436
87. Es-0010
88. Lp01110
89. Sdccgsbi-0051079.p003
90. Us11001595, Compound Su5416
91. Ncgc00094381-01
92. Ncgc00094381-02
93. Ncgc00094381-04
94. Ncgc00094381-05
95. Ncgc00094381-19
96. Ncgc00261795-01
97. Ac-35250
98. Hy-10374
99. Eu-0101110
100. Sw219791-1
101. D05819
102. N11132
103. A857052
104. A899499
105. 2h-indol-2-one,5-dimethyl-2-pyrrolyl)methylene]-
106. J-013281
107. Q7449140
108. Sr-01000076044-2
109. Sr-01000076044-8
110. Brd-k63504947-001-05-5
111. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinon
112. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone
113. 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)indolin-2-one
114. Semaxanib, Semoxind, Tsu-16, Nsc-696819, Su-5416
115. 3-[(3,5-dimethyl-2h-pyrrol-2-ylidene)methyl]-1h-indol-2-ol
116. 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro- 2h-indol-2-one
117. 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one
118. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one
119. 2h-indol-2-one, 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)-1,3-dihydro-, (3z)-
120. 2h-indol-2-one, 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)-1,3-dihydro-, (z)-
121. 2h-indol-2-one, 3-(3,5-dimethyl-1h-pyrrol-2-yl)methylene)- 1,3-dihydro-, (z)-
122. 2h-indol-2-one, 3-(3,5-dimethyl-1h-pyrrol-2-yl)methylene)- 1,3-dihydro-,(z)-
123. 2h-indol-2-one,3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-, (3z)-
124. 3-[1-(3,5-dimethyl-1h-pyrrol-2-yl)-meth-(z)-ylidene]-2-oxo-2,3-dihydro-indole
| Molecular Weight | 238.28 g/mol |
|---|---|
| Molecular Formula | C15H14N2O |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 1 |
| Exact Mass | 238.110613074 g/mol |
| Monoisotopic Mass | 238.110613074 g/mol |
| Topological Polar Surface Area | 44.9 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 377 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in colorectal cancer and lung cancer.
Angiogenesis Inhibitors
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. (See all compounds classified as Angiogenesis Inhibitors.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
NDC Package Code : 68225-104
Start Marketing Date : 2019-08-02
End Marketing Date : 2026-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (125ug/.25mL)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 68225-049
Start Marketing Date : 2008-08-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (0.4mg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 68225-050
Start Marketing Date : 2008-08-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (0.6mg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC Package Code : 68225-050
Start Marketing Date : 2008-08-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (0.6mg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 68225-049
Start Marketing Date : 2008-08-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (0.4mg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 68225-104
Start Marketing Date : 2019-08-02
End Marketing Date : 2026-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (125ug/.25mL)
Marketing Category : DRUG FOR FURTHER PROCESSING

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
QL0911 (Romiplostim) is a antibody drug, which is currently being evaluated in Phase III clinical studies for the treatment of purpura, thrombocytopenic, idiopathic.
Lead Product(s): Semaxanib,Inapplicable
Therapeutic Area: Immunology Brand Name: QL0911
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Semaxanib,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Details : QL0911 (Romiplostim) is a antibody drug, which is currently being evaluated in Phase III clinical studies for the treatment of purpura, thrombocytopenic, idiopathic.
Product Name : QL0911
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 06, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VAY736 (Ianalumab) is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of purpura, thrombocytopenic, idiopathic.
Lead Product(s): Ianalumab,Eltrombopag,Avatrombopag Maleate,Semaxanib
Therapeutic Area: Immunology Brand Name: VAY736
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 19, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ianalumab,Eltrombopag,Avatrombopag Maleate,Semaxanib
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VAY736 (Ianalumab) is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of purpura, thrombocytopenic, idiopathic.
Product Name : VAY736
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 19, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Romiplostim N01 (Romiplostim) is a protein drug, which is currently being evaluated in Phase III clinical studies for the treatment of anemia, aplastic.
Lead Product(s): Semaxanib,Cyclosporine,pALG/ rATG
Therapeutic Area: Hematology Brand Name: Romiplostim N01
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 15, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Semaxanib,Cyclosporine,pALG/ rATG
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Romiplostim N01 (Romiplostim) is a protein drug, which is currently being evaluated in Phase III clinical studies for the treatment of anemia, aplastic.
Product Name : Romiplostim N01
Product Type : Protein
Upfront Cash : Inapplicable
January 15, 2026

Details:
Ruxolitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Splenomegaly.
Lead Product(s):
Ruxolitinib Phosphate,Allogeneic Stem Cell Transplant,Levetiracetam,Eltrombopag,Busulfan,Semaxanib,Fludarabine Phosphate,Cyclophosphamide,Mesna,
Therapeutic Area: Hematology
Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous Sponsor:
Incyte Corporation
Deal Size: Inapplicable
Upfront Cash: Inapplicable
Deal Type: Inapplicable
April 03, 2024

Lead Product(s) : Ruxolitinib Phosphate, Levetiracetam, Eltrombopag, Busulfan, Semaxanib
Therapeutic Area : Hematology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ruxolitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Splenomegaly.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
GP40141 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): GP40141,Semaxanib
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 15, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GP40141,Semaxanib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GP40141 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 15, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Romiplostim is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia, Aplastic.
Lead Product(s): Semaxanib,Antithymocyte Globulin,Cyclosporine
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 12, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Semaxanib,Antithymocyte Globulin,Cyclosporine
Therapeutic Area : Hematology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Romiplostim is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia, Aplastic.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 12, 2022

Details:
Lomustine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.
Lead Product(s): Lomustine,Semaxanib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Amgen Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 22, 2021

Details : Lomustine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 22, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Romiplostim is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.
Lead Product(s): Semaxanib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: Amgen Inc | Tel Aviv Sourasky Medical Center (Ichilov Hospital)
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 17, 2020

Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
Details : Romiplostim is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 17, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Romiplostim is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Lead Product(s): Semaxanib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: Amgen Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 20, 2020

Details : Romiplostim is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 20, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Romiplostim is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bone Marrow Failure Disorders.
Lead Product(s): Semaxanib,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: Anjali Sharathkumar
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 20, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Semaxanib,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Anjali Sharathkumar
Deal Size : Inapplicable
Deal Type : Inapplicable
TPO-Mimetic Use in Children for Hematopoietic Failure
Details : Romiplostim is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bone Marrow Failure Disorders.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 20, 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 59-48-3
End Use API : Semaxanib
About The Company : Sunway Pharm ltd provides high quality building blocks to the global pharmaceutical and bio-technology industry. Combining our chemistry expertise and our econo...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : NPLATE
Dosage Form : INJECTABLE; SUBCUTANEOUS
Dosage Strength : 250MCG/0.5ML; 500MCG/1ML.
Packaging :
Approval Date :
Application Number : 125268
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : Nplate
Dosage Form : Romiplostim 250Mcg 0.72Ml 1 Units Parenteral Use
Dosage Strength : 1 vial 250 mcg groun + solv
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : Nplate
Dosage Form : Romiplostim 500Mcg 1,2Ml 1 Unit Parenteral Use
Dosage Strength : 1 vial 500 mcg groun + solv
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Nplate
Dosage Form : Solution For Injection
Dosage Strength : 250mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Nplate
Dosage Form : Solution For Injection
Dosage Strength : 500mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Nplate
Dosage Form : Powder For Solution For Injection
Dosage Strength : 125mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Not Marketed
Registration Country : Norway
Brand Name : Nplate
Dosage Form : Powder For Solution For Injection
Dosage Strength : 250mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Not Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Not Marketed
Registration Country : Norway
Brand Name : Nplate
Dosage Form : Powder For Solution For Injection
Dosage Strength : 500mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Not Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Brand Name : Nplate
Dosage Form : Powder For Solution For Injection
Dosage Strength : 125mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Brand Name : Nplate
Dosage Form : Powder For Solution For Injection
Dosage Strength : 250mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
87
PharmaCompass offers a list of Semaxanib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Semaxanib manufacturer or Semaxanib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Semaxanib manufacturer or Semaxanib supplier.
A NPLATE manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of NPLATE, including repackagers and relabelers. The FDA regulates NPLATE manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. NPLATE API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A NPLATE supplier is an individual or a company that provides NPLATE active pharmaceutical ingredient (API) or NPLATE finished formulations upon request. The NPLATE suppliers may include NPLATE API manufacturers, exporters, distributors and traders.
click here to find a list of NPLATE suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing NPLATE as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for NPLATE API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture NPLATE as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain NPLATE and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a NPLATE NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of NPLATE suppliers with NDC on PharmaCompass.
NPLATE Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of NPLATE GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right NPLATE GMP manufacturer or NPLATE GMP API supplier for your needs.
A NPLATE CoA (Certificate of Analysis) is a formal document that attests to NPLATE's compliance with NPLATE specifications and serves as a tool for batch-level quality control.
NPLATE CoA mostly includes findings from lab analyses of a specific batch. For each NPLATE CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
NPLATE may be tested according to a variety of international standards, such as European Pharmacopoeia (NPLATE EP), NPLATE JP (Japanese Pharmacopeia) and the US Pharmacopoeia (NPLATE USP).